The present invention relates to substituted imidazolidin-2-one derivatives of formula (I) or pharmaceutically acceptable salts thereof. The present invention further provides the methods of preparation of compound of formula (I) and utility as PRMT5 inhibitors. The compounds are useful as medicaments in the treatment of conditions and disorders mediated by PRMT5, such as cancer, metabolic disorders, inflammation, autoimmune disease and hemoglobinopathies.

The present invention relates to substituted imidazolidin-2-one derivatives of formula (I) or pharmaceutically acceptable salts thereof. The present invention further provides the methods of preparation of compound of formula (I) and utility as PRMT5 inhibitors. The compounds are useful as medicaments in the treatment of conditions and disorders mediated by PRMT5, such as cancer, metabolic disorders, inflammation, autoimmune disease and hemoglobinopathies.

This application relates to compounds of Formula (I):

##STR00001##

or pharmaceutically acceptable salts thereof, which are inhibitors of PI3K-γ which are useful for the treatment of disorders such as autoimmune diseases, cancer, cardiovascular diseases, and neurodegenerative diseases.

The present invention provides compounds of formula I: ##STR00001##
or a pharmaceutically acceptable salt, tautomer, or stereoisomer thereof, wherein the variables are as defined herein. The present invention further provides pharmaceutical compositions comprising such compounds, and methods of using such compounds for treatment of joint damage or joint injury in a mammal, and for inducing differentiation of mesenchymal stem cells into chondrocytes.

The present invention provides compounds of formula I: ##STR00001##
or a pharmaceutically acceptable salt, tautomer, or stereoisomer thereof, wherein the variables are as defined herein. The present invention further provides pharmaceutical compositions comprising such compounds, and methods of using such compounds for treatment of joint damage or joint injury in a mammal, and for inducing differentiation of mesenchymal stem cells into chondrocytes.

Present invention is related to a polyimide of formula as following:

##STR00001##

and a ketone-containing alicyclic dianhydride of formula as following:

##STR00002##

wherein: R1, R2, R3, R4 denote hydrogen atom or carbon containing functional group with carbon number at a range of 1-4; R5 denotes diamine group; and n equals to any positive integer.

Present invention is related to a polyimide of formula as following:

##STR00001##

and a ketone-containing alicyclic dianhydride of formula as following:

##STR00002##

wherein: R1, R2, R3, R4 denote hydrogen atom or carbon containing functional group with carbon number at a range of 1-4; R5 denotes diamine group; and n equals to any positive integer.

Various embodiments of the present invention are directed to compounds of the formula (I) or a pharmaceutically acceptable salt, polymorph, prodrug, solvate or clathrate thereof. The compounds disclosed herein are as inhibitors of HIV-1 protease and, as a result, are useful in the treatment of HIV infection.

Various embodiments of the present invention are directed to compounds of the formula (I) or a pharmaceutically acceptable salt, polymorph, prodrug, solvate or clathrate thereof. The compounds disclosed herein are as inhibitors of HIV-1 protease and, as a result, are useful in the treatment of HIV infection.

Provided is a compound that may have a superior CDK12 inhibitory action and is expected to be useful as a prophylactic or therapeutic drug for cancer and the like. A compound represented by the following formula (I): ##STR00001##
wherein each symbol is as described in the DESCRIPTION, or a salt thereof.